Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

amaxa to Co-ordinate Collaboration to Develop High Throughput Devices for Primary Cell Transfection

Published: Monday, July 02, 2007
Last Updated: Monday, July 02, 2007
Bookmark and Share
amaxa receives a €2.75M grant from European Commission to develop devices for use in the study of immunological, neuronal and liver disorders.

amaxa AG has announced that it will co-ordinate a European collaboration of eight partners to develop devices for ultra high-throughput delivery and screening of primary cells, for use in the study of immunological, neuronal and liver disorders.

The collaboration has been granted over €2.75 million in funding from the EC and will use amaxa’s Nucleofector® Technology – a method for the transfection of primary cells.

The 36-month project, named MODEST-EU, is a collaboration between amaxa AG (Germany), Deutsches Rheumaforschungszentrum (Germany), RNAx GmbH (Germany), Protobios Ltd (Estonia), Fotec Forschungs- und Technologietransfer GmbH (Austria), HTP High Tech Plastics AG (Austria), Dominion Pharmakine SL (Spain) and Prevas AB (Sweden).

The devices developed using amaxa’s Nucleofector® Technology will represent the world’s first technology enabling high-throughput screenings in transfected and differentiated primary cells. The project will go on to study the application of this technology in the areas of immunology, neurology and liver disorders.

Dr. Birgit Nelsen-Salz, coordinator of the project, said “amaxa is the only institution worldwide, which has the necessary knowledge and experience to adapt the technical needs of device development to the conditions used for efficient transfection of primary cells and hard-to-transfect cell lines. As co-ordinator of the project we will ensure that the expertise brought by each partner will enable the collaboration to achieve the goal of providing powerful new tools for basic research and drug discovery”.

Each partner will play a significant role in the development of the devices: Prevas will be responsible for the building of the device from proof-of-principle up to prototype; Fotec will develop the production process for micro-plates; HTP will be involved in the prototyping of the 384-well plates.

In addition, the application of nucleofection and cell based assays will be assessed by a team of outstanding experts: DRFZ (cell sorting and multiparameter flow-cytometry), RNAx (RNAi technology), Protobios (nervous system development and transcription regulation network) and Dominion Pharmakine (biomarkers related to site specific development of liver metastasis).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Amaxa to Host Webinar on the Nucleofection® of Stem Cells
The webinar imparts knowledge about setting up embryonic, mesenchymal, hematopoietic or neural stem cell experiments using Nucleofector® Technology.
Thursday, May 01, 2008
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Biological Link between the Gut Microbiome and Parkinson’s Disease
The findings suggest that targeting the gut microbiome may provide a new approach for diagnosing and treating Parkinson’s disease.
How the Brain Recognizes Faces
Machine-learning system spontaneously reproduces aspects of human neurology.
Boosting Effectiveness of Asthma Therapy
A team of scientists from UCSF has developed a new treatment to dampen bronchospasm.
Improved Stability, Shelf Life of Protein Drugs
Study improves protein drug stability and extend their shelf life by tested a novel route for non-covalent protein modification.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!